Source: FE Investegate

PledPharma: PledPharma AB : First Asian patient has been included in the global Phase III program for PledOx® and will trigger a milestone payment of 600 MJPY (c.49 MSEK) to PledPharma

7:00 AM: First Asian patient has been included in the global Phase III program for PledOx® and will trigger a milestone payment of 600 MJPY (c.49 MSEK) to PledPharma

Read full article »

PledPharma's Competitors | PledPharma's News | PledPharma's Financials

Followers on Owler

1

Est. Annual Revenue

$5.0-25M

Est. Employees

25-100

CEO

Nicklas Westerholm

CEO Approval Rating

70/100

PledPharma develops and commercializes drugs for the treatment of life-threatening diseases caused by chemotherapy and paracetamol poisoning.